Passage BIO, Inc.
PASGDrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 11, 2026
7dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
PASG Earnings Report
EPS Est: $-1.93 | FQ end 2026-06
How PASG's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
PBFT02 | Phase 2 | Frontotemporal Dementia | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Passage BIO, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Passage BIO, Inc.'s (PASG) pipeline across Phase 2. Its lead program is PBFT02 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Passage BIO, Inc.'s next FDA catalyst?→
Passage BIO, Inc.'s (PASG) next tracked catalyst is a Earnings expected August 11, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track PASG biotech catalysts?→
Add PASG to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Passage BIO, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.